PACB · 3 developments mapped · last assessed 2026-09-25
Market Ontology has mapped 3 macro, policy, and market developments to Pacific Biosciences of California, Inc. since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for PACB yet, so no modelled value is shown. The PACB valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run PACB on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for PACB. Missing data is not estimated or replaced with scenario assumptions.
Current case
Strongest support
Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
Increased demand for genomic sequencing and synthetic biology tools and consumables as the sector grows and secures more funding.
· Moves market size growth, equipment utilization
Open question
Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal
Increased investor interest in genomics/synthetic biology tools, potential for similar partnerships.
· Moves market growth for genomics tools, investor sentiment towards biotech innovation
What changed, by assumption
Market growth for genomics tools
2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal
Investor sentiment
2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform
Market size growth
2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants